Q1FY27 Consolidated Financial Performance

Sakar Healthcare Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27).

Financial Highlights:

| Particulars (INR Lakhs) | Q1FY27 | Q1FY26 | Y-o-Y Growth | FY26 Full Year |

| Revenue from Operations | 7,297.25 | 5,273.62 | 38% | 25,173.60 |

| Gross Profit | 3,839.03 | 2,378.38 | 61% | 12,845.93 |

| Gross Profit Margin (%) | 53% | 45% | | 51% |

| EBITDA | 2,124.89 | 1,270.58 | 67% | 6,888.82 |

| EBITDA Margin (%) | 29% | 24% | | 27% |

| Profit After Tax | 1,028.49 | 467.13 | 120% | 3,048.46 |

| PAT Margin (%) | 14% | 9% | | 12% |

Performance Drivers:

  • Revenue growth of 38% YoY was supported by new market authorizations with oncology products and strong demand across countries
  • Significant margin expansion with Gross Profit Margin improving to 53% from 45% YoY and EBITDA Margin improving to 29% from 24% YoY
  • PAT margin expanded sharply to 14% from 9% YoY, reflecting operating leverage, improved efficiencies, and disciplined cost management

Business Highlights for Q1FY27

Commercial and Regulatory Progress:

  • Executed more than 65 oncology product contracts
  • Over 50 commercial discussions currently underway
  • Shared 261 dossiers globally, with 178 submitted and 16 receiving Marketing Authorisations
  • Shared dossiers for 21 of the 32 developed oncology products, securing 16 dossier approvals
  • Completed 26 EU Marketing Authorisation filings, including 15 owned filings
  • 6 Marketing Authorisations procured through partners in Bulgaria and Bosnia
  • Additional filings in Czech Republic, Croatia, and Portugal
  • Submitted 33 site variations covering 18 cytotoxic molecules across the EU and UK, with seven approved

API Development and Technology Transfer:

  • Developed 21 APIs in-house
  • 16 APIs with Written Confirmation
  • 8 Commercialised products
  • 2 APIs with CEP approval
  • 5 CEP applications currently in process
  • 33 Technology transfer projects for oncology products underway with Accord-Intas, Torrent in the UK and Germany, Emcure, Glenmark, and Zydus
  • 7 projects received site variation approvals (two in the UK and five in the EU)

Management Commentary

Mr. Sanjay Shah, Managing Director, commented:

"Q1FY27 marks another period of steady progress, supported by healthy year-on-year growth. The company remains on a strong growth trajectory in terms of both revenue and profitability, reinforcing the promising outlook for the business over the longer term. Our Oncology business remains a key pillar of our strategy. During the quarter, we expanded commercial engagements, strengthened export momentum, and advanced dossier submissions, Marketing Authorizations, site variation approvals, and technology transfer projects with leading global pharmaceutical partners. We also enhanced our integrated oncology platform by expanding our portfolio of inhouse APIs supported by key regulatory certifications, reinforcing our capabilities and long-term competitive position.

Looking ahead, we remain confident that converting regulatory approvals into commercial launches and supplies, alongside growing export opportunities and the gradual ramp-up of oncology volumes, will improve capacity utilisation and operating leverage. Backed by a robust product pipeline, regulatory progress, and an expanding international presence, we are well positioned to deliver sustainable and profitable growth. Our long-term outlook remains promising, underpinned by the scalability of our oncology platform and the progressive commercialization of our product portfolio."

Company Background

Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. Established in 2004 and headquartered in Ahmedabad, Gujarat, the company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. The oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs. With a global footprint across more than 60 countries, Sakar serves multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations.